| Autor: |
Jakobsen, Anders, Mortensen, John Pløen, Bisgaard, Claus, Lindebjerg, Jan, Rafaelsen, Søren Rafael, Bendtsen, Vagn Ove |
| Předmět: |
|
| Zdroj: |
International Journal of Colorectal Disease; Mar2008, Vol. 23 Issue 3, p251-255, 5p, 4 Charts |
| Abstrakt: |
The aim of this study was to investigate the possible effect of a COX-2 inhibitor in addition to chemoradiation of locally advanced rectal cancer. The study included 35 patients with rectal adenocarcinoma. All patients had a tumor localised ≤10 cm from the anal verge and a circumferential margin ≤5 mm on a magnetic resonance scan. The patients were scheduled to receive external radiation with a tumor dose of 60 Gy supplemented with an endorectal boost of 5 Gy. Concurrent with radiation, the patients received uracil-tegafur 300 mg/m2 daily. Celexocib was scheduled throughout the radiation period in a dose of 400 mg × 2 daily. A macular papular rash was seen in 17 (49%) of the patients leading to stop of medication with celecoxib. Thirty-three patients were operated, and all patients responded to treatment. Complete pathological remission was found in 21% of the patients and further 24% had only microscopic residual tumor cells. The results did not suggest any difference according to the accomplishment of the COX-2 medication. The addition of a COX-2 inhibitor to chemotherapy-enhanced radiation treatment of rectal cancer was not feasible due to a high incidence of rash in the present study. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink